## A Concise Synthesis of $(\pm)$ -, (+)-, and (-)-6-Methyl-6-azabicyclo[3.2.1]octan-3 $\alpha$ -ol

## Abraham Philip,<sup>a</sup> J. Bruce Pitner,<sup>a</sup> Young J. Joo,<sup>a</sup> David J. Triggle,<sup>b</sup> and F. Ivy Carroll\*<sup>a</sup>

- <sup>a</sup> Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, USA
- Department of Biochemical Pharmacology, School of Pharmacy, State University of New York at Buffalo, Buffalo, New York 14260, USA

( $\pm$ )-6-Methyl-6-azabicyclo[3.2.1]octan-3-one (**1c**) was prepared in three steps from 6-oxabicyclo[3.2.1]oct-3-en-7-one, and stereoselective reduction of (**1c**) provided ( $\pm$ )-6-methyl-6-azabicyclo[3.2.1]octan-3 $\alpha$ -ol (**1a**); adaptation of the sequence provided the first synthesis of (+)- and (-)-(**1a**).

6-Methyl-6-azabicyclo[3.2.1]octan-3 $\alpha$ -ol (1a) is the key intermediate for the synthesis of 6-methyl-6-azabicyclo[3.2.1]-octan-3 $\alpha$ -ol 2,2-diphenylpropionate (1b, azaprophen), a novel, conformationally restricted, highly potent antimuscarinic analogue of atropine. In order to prepare additional muscarinic agonists and antagonists as potential drugs for the treatment of Alzheimers disease, a more convenient higher yield synthesis of (1a) was needed.

Initially, alcohol (1a) was prepared by lithium aluminium hydride reduction of 6-methyl-6-azabicyclo[3.2.1]octan-3-one (1c) which was prepared by a modification of the procedure reported by Furstoss and co-workers.<sup>3</sup> Even though the modifications offered a better synthesis of (1c), a simpler, higher yield method was needed. This need led us to investigate the sequence shown in Scheme 1, which starts with the readily available lactone 6-oxabicyclo[3.2.1]oct-3-en-7-one (2).<sup>4,5</sup> When lactone (2) was treated with a methanolic solution of methylamine at 100 °C, a nearly quantitative yield of the amide (3)† was obtained. Lithium aluminium hydride

Me 
$$R^{1}$$
  $R^{2}$   $R^{1}$  = OH,  $R^{2}$  = H  
b;  $R^{1}$  =  $Ph_{2}CMeCO_{2}$ ,  $R^{2}$  = H  
c;  $R^{1}$ ,  $R^{2}$  = O  $R^{2}$   
d;  $R^{1}$  = H,  $R^{2}$  = OH

(8) 
$$R^1$$
,  $R^2 = -0$ ,  $R^3 = PhCHMeNH_2$  (9)  
(10)  $R^1 = OH$ ,  $R^2 = H$ ,  $R^3 = PhCHMeNH_2$  (11)

(-) - (1a) 
$$R^1$$
 = OH,  $R^2$  = H,  $R^3$  = Me (+) - (1a)

(-) - (1e) 
$$R^1 = MeCO_2$$
,  $R^2 = H$ ,  $R^3 = Me$  (+) - (1e)

reduction of (3) afforded the hydroxy amine (4). Allylic oxidation of (4) using activated manganese dioxide in methylene chloride solution gave the  $\alpha,\beta$ -unsaturated ketone (5) which spontaneously cyclized to give the desired azabicyclic ketone (1c) in 78% overall yield from (2). The ketone (1c) is conveniently stored as the hydrochloride salt, m.p. 157—158 °C. Since reduction of (1c) with lithium aluminium hydride gave a 60:40 mixture of (1a) and (1d), we examined other methods for this conversion. When (1c) was reduced with L-Selectride (LiBus 3BH), an 85% yield of >97% pure (1a) was obtained.‡

When lactone (2) was treated with (R)-(+)- $\alpha$ -methylbenzylamine, an 81% yield of a 1:1 mixture of the diastereo-isomers (6) and (7) was obtained. Flash chromatography on silica gel using a diethyl ether-ethyl acetate gradient was found to resolve the mixture of (6) and (7).§ The earlier eluting isomer (6) had m.p. 163—164 °C,  $[\alpha]_D^{24}$  +98° (c 1, CHCl<sub>3</sub>), whereas the other isomer (7) had m.p. 155.5—157 °C,  $[\alpha]_D^{24}$  +81.6° (c 1, CHCl<sub>3</sub>). The absolute stereochemistry of (6) and (7) was shown to be (1R,5R) and (1S,5S) respectively by establishing that (-)-(1S,5S)-6-oxabicyclo[3.2.1]oct-3-en-7-one6¶ gave (7) on treatment with (R)-(+)- $\alpha$ -methylbenzylamine.

Scheme 1. Reagents and conditions: i, MeNH<sub>2</sub>, MeOH,  $100\,^{\circ}$ C; ii, LiAlH<sub>4</sub>, tetrahydrofuran (THF), reflux; iii, MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C; iv, L-Selectride, THF, -78 to  $0\,^{\circ}$ C.

<sup>†</sup> All new compounds gave satisfactory analysis.

<sup>‡</sup> None of the isomer (1d) could be detected by ¹H NMR (250 MHz) analysis of the reaction mixture.

<sup>§</sup> HPLC analyses (ethyl acetate, Dynamax 60A silica column, 2 ml/min flow rate, 256 nm UV detection) indicated >98% diastereo-isomeric purity.

<sup>¶</sup> The absolute stereochemistry of (+)-(2) and (-)-(2) has been established (ref. 6).

View Article Online

Subjection of (6) and (7) to the reaction sequence shown for (3) in Scheme 1 provided the optically active azabicyclic ketones (8) {m.p.  $65-66^{\circ}$ C,  $[\alpha]_{D}^{24}+17.7^{\circ}$  (c 1, CHCl<sub>3</sub>)} and (9) {m.p.  $60-61^{\circ}$ C,  $[\alpha]_{D}^{24}+9.5^{\circ}$  (c 1, CHCl<sub>3</sub>)}, respectively. L-Selectride reduction of (8) and (9) gave 84% of (10) {m.p. 125-126 °C,  $[\alpha]_{D}^{23}-4.4^{\circ}$  (c 1, CHCl<sub>3</sub>)} and 98% of (11) {m.p.  $78.5-80^{\circ}$ C,  $[\alpha]_{D}^{23}+20.3^{\circ}$  (c 1, CHCl<sub>3</sub>)}, respectively. Catalytic debenzylation (Pd/C, MeOH, H<sub>2</sub>) followed by catalytic reductive amination [Pd/C, MeOH, H<sub>2</sub>, (CH<sub>2</sub>O)<sub>n</sub>] of (10) gave 79% of (-)-(1R,5S,3R)-(1a) as an oil, which was characterized as the resorcylate salt of the 3-acetate {(-)-(1e)}; m.p.  $165-167^{\circ}$ C,  $[\alpha]_{D}^{24}-7.8^{\circ}$  (c 0.75, MeOH)}. Similar treatment of (11) gave (+)-(1S,5R,3S)-(1a); also characterized as the resorcylate salt of the 3-acetate {(+)-(1e)}, m.p.  $166-167^{\circ}$ C,  $[\alpha]_{D}^{24}+8.0^{\circ}$  (c 0.75, MeOH)}.

In summary, we have developed a short, efficient, high-yield synthesis of  $(\pm)$ -6-methyl-6-azabicyclo[3.2.1]octan-3-one (1c) and studied its stereoselective reduction to the corresponding  $\alpha$ -alcohol (1a).

This research was supported by Grant AG-07418 from the National Institute on Aging.

Received, 12th March 1990; Com. 0/01089H

## References

- F. I. Carroll, P. Abraham, K. Parham, R. C. Griffith, A. Ahmad, M. M. Richard, F. N. Padilla, J. M. Witkin, and P. C. Chiang, J. Med. Chem., 1987, 30, 805.
- 2 For recent reviews on Alzheimers disease see: 'Current Research in Alzheimers Therapy,' eds. E. Giacobini and R. Becker, Taylor and Francis, New York, 1988; W. Armstrong, 'Recent Trends in Research on Alzheimers Disease,' PJB Publications, Ltd, Surrey, 1986
- 3 R. Furstoss, P. Teissier, and B. Waegell, Chem. Commun., 1970, 384; R. Furstoss, G. Esposito, P. Teissier, and B. Waegell, Bull. Soc. Chim. Fr., 1974, 2485.
- 4 P. A. Bartlett and L. A. McQuaid, J. Am. Chem. Soc., 1984, 106, 7854.
- 5 T. Inukae and M. Kasai, J. Org. Chem., 1965, 30, 3567.
- 6 S. F. Martin, M. S. Dappen, B. Dupre, C. J. Murphy, and J. A. Colapret, J. Org. Chem., 1989, 54, 2209.